These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30541878)

  • 1. Pharmacokinetics, Metabolism, and Excretion of [
    Yamada M; Mendell J; Takakusa H; Shimizu T; Ando O
    Drug Metab Dispos; 2019 Mar; 47(3):340-349. PubMed ID: 30541878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys.
    Yamada M; Takei M; Suzuki E; Takakusa H; Kotsuma M; Washio T; Murayama N; Inoue SI; Izumi T
    Xenobiotica; 2017 Dec; 47(12):1090-1103. PubMed ID: 27866463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
    Kurata A; Furuie H; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2019 Jul; 36(7):1618-1627. PubMed ID: 31119692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
    Toyama K; Furuie H; Kuroda K; Ishizuka T; Okuda Y; Shimizu T; Kato M; Igawa Y; Nishikawa Y; Ishizuka H
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):685-694. PubMed ID: 34383278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
    Watanabe A; Ishizuka T; Yamada M; Igawa Y; Shimizu T; Ishizuka H
    Eur J Clin Pharmacol; 2022 Jan; 78(1):65-73. PubMed ID: 34415382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):55. PubMed ID: 32727577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
    Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation Pathways and Metabolite Profiles of Oral [
    Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
    Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excretion, Mass Balance, and Metabolism of [
    Katyayan K; Yi P; Monk S; Cassidy K
    Drug Metab Dispos; 2020 Aug; 48(8):698-707. PubMed ID: 32499340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
    Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
    Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, Metabolism, Distribution, and Excretion of Letermovir.
    Menzel K; Kothare P; McCrea JB; Chu X; Kropeit D
    Curr Drug Metab; 2021; 22(10):784-794. PubMed ID: 33622223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
    Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
    Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.